Cargando…

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Minimal residual disease (MRD) is associated with adverse outcome in AML after myeloablative (MA) hematopoietic cell transplantation (HCT). We compared this association with that seen after nonmyeloablative (NMA) conditioning in 241 adults receiving NMA (n=86) or MA (n=155) HCT for AML in first remi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Roland B., Gyurkocza, Boglarka, Storer, Barry E., Godwin, Colin D., Pagel, John M., Buckley, Sarah A., Sorror, Mohamed L., Wood, Brent L., Storb, Rainer, Appelbaum, Frederick R., Sandmaier, Brenda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254901/ https://www.ncbi.nlm.nih.gov/pubmed/24888275 http://dx.doi.org/10.1038/leu.2014.173

Ejemplares similares

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
por: Jaklič, Alenka, et al.
Publicado: (2013)

Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML
por: Morsink, Linde M., et al.
Publicado: (2020)

Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission
por: Walter, Roland B., et al.
Publicado: (2010)

Role of Comorbidities in Optimizing Decision-Making for Allogeneic Hematopoietic Cell Transplantation
por: Sorror, Mohamed L., et al.
Publicado: (2010)

(GT)(n) Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Køllgaard, Tania, et al.
Publicado: (2016)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR
por: Wieduwilt, Matthew J., et al.
Publicado: (2021)

Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Zarling, Lucas C., et al.
Publicado: (2022)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
por: Luger, Selina M., et al.
Publicado: (2011)

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Rodríguez-Arbolí, Eduardo, et al.
Publicado: (2022)

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Morsink, Linde M., et al.
Publicado: (2020)

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
por: Sandmaier, Brenda M., et al.
Publicado: (2017)

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation
por: Kanda, Junya, et al.
Publicado: (2011)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation
por: Castilla-Llorente, Cristina, et al.
Publicado: (2014)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
por: Bar, Merav, et al.
Publicado: (2014)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
por: Gyurkocza, Boglarka, et al.
Publicado: (2023)

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
por: Orvain, Corentin, et al.
Publicado: (2023)

The Quality of Life of Adult Survivors of Childhood Hematopoietic Cell Transplant
por: Sanders, Jean E., et al.
Publicado: (2009)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update
por: Erotocritou, P., et al.
Publicado: (2006)

Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation
por: Toh, H C, et al.
Publicado: (2011)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
por: Banna, G L, et al.
Publicado: (2006)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
por: Long-Boyle, Janel R, et al.
Publicado: (2010)

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity
por: Stephens, Sarah J., et al.
Publicado: (2016)

cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies
por: Li, Yawen, et al.
Publicado: (2018)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vdjanfc6gc1ue4klapdfbfifdc